AMEET NATHWANI
A U.K. citizen, born in Uganda and educated in the U.K., Dr Nathwani qualified in medicine in 1987 in London, acquired his specialization in Cardiology at a number of University Hospitals in London, and has a diploma in Pharmaceutical Medicine and an executive Masters in Business Administration.
Dr. Nathwani has more than 20 years of experience in the pharmaceutical industry beginning in 1994 when he joined Glaxo Group Research. From the period of 1994 to 2004 he held increasingly senior global functional and franchise leadership roles in research and development in Glaxo, SmithKline Beecham and GlaxoSmithKline, both in Europe and the US. He joined Novartis in 2004 as the Senior Vice President and Global Development Head of the Cardiovascular and Metabolic Franchise and over the period of 11 years has held a number of senior development and commercial positions including the Global Head of the Critical Care Business Franchise. He was appointed as Global Head of Medical Affairs Novartis Pharma AG in June 2014 and became an extended member of the Pharma Executive Committee where he led the establishment of a Real World Evidence Center of Excellence and Digital Medicine capability.
He was appointed Chief Medical Officer in May 2016 and Chief Digital Officer in February 2019.
Krishna Bahadursingh
Dr Krishna Bahadursingh joined Syneos Health in Tokyo, Japan, as Regional Vice President, Medical APAC/Japan on July 1st. His main responsibility would be to build out the Medical Affairs function to capitalize on the available opportunities and for Syneos in Japan/Asia Pacific.
He joined the pharma industry from clinical practice, working for both Japanese headquartered and MNC companies and spent more than two decades in multi- disciplinary, thought- leadership roles central to ensuring patient safety and regulatory compliance as well as spearheading evolution in the medical affairs function from a support organization to a value-added one fully dedicated to delivering favorable reported outcomes for both patients and their families.
Krishna has resided primarily in Tokyo, Japan for the past 20 years but has also lived or worked in a number of countries in Asia. In addition to his medical qualifications and experience he is a Fellow of the Royal College of Surgeons (FRCS), Fellow of the of the Faculty of Pharmaceutical Medicine (FFPM), holds an Executive MBA and is also an attorney-at-law (LLB). He is a member of the Association of Medical Doctors in Asia AMDA).
Cezary Statuch
Dr Cezary Statuch joined Biogen in January 2015 and is currently the Vice President of Medical for the region of International Markets. His career in the pharmaceutical industry spans almost 30 years. During his professional life Cezary has held positions in clinical research operations, global drug development and medical affairs. Prior to joining Biogen, Cezary led the China Research and Development team for Bristol-Myers Squibb. He was involved in managing activities in China for almost 15 years, 7 of which he spent living in Shanghai. Cezary is actively engaged in the training and education of physicians in the healthcare industry across many emerging and established markets. He is a founding member of the China Medical Affairs Network. He is also a member of the Executive Committee of the Medical Affairs Professional Society. Cezary is passionate about promoting access to medicines across Emerging Markets to address unmet medical needs and help patients to prevail against serious medical conditions.
KAREN WOOLLEY
Karen is the Global Lead for Patient Partnerships at Envision Pharma Group and oversees staff in Envision’s Tokyo and Sydney offices. She has 30 years of experience in the healthcare sector, gained in academia, hospital, industry (Pfizer, Johnson & Johnson), and agency (ProScribe Medical Communications, Envision Pharma Group) environments, in North America and the Asia Pacific region. Karen has a strong focus on strategic initiatives in the medical affairs sector and has led international teams to conduct and publish research on publications ethics and on patient engagement and involvement in industry-sponsored research. Karen is a Professor at two universities and has been a government-appointed director overseeing 6 hospitals, serving on the Patient Safety and Quality Committee, and managing a $2B budget. She was the inaugural chair of the Asia Pacific Advisory Committee for the International Society of Medical Publication Professionals, is an Honorary Fellow of the American Medical Writers Association, a Life Member of the Australasian Society of Clinical and Regulatory Scientists (ARCS), an Editorial Board Member for the Research Integrity and Peer Review journal, and is the only author from the Asia Pacific region on the international Good Publication Practice for Communicating Company-Sponsored Research (GPP3) guidelines and the Joint Position Statement on the Role of Professional Medical Writers. Karen is regularly invited to present her research and share her insights at major international and regional conferences.
ZHIHUI (ZIG) LANG
Dr. Lang is the Senior Vice President and Head of Medical Affairs and Pharmacovigilance at Bayer Healthcare China including Hong Kong. In this role, Dr. Lang directs the Medical Affairs, Medical Science Liaisons, Medical Communications, Scientific Operations, Medical Compliance, Patient Support and Disease Management Programs, Health Economics and Outcome Research and Pharmacovigilance.
Prior to coming to Bayer China, Dr. Lang worked in Bayer’s Global Medical Affairs Oncology in the United States. Dr. Lang has over 18 years of pharmaceutical industry experiences ranging from early and late stage clinical development to medical affairs. Dr. Lang held positions with increasing responsibilities at Endo Pharmaceuticals, Johnson and Johnson, Wyeth and Novo Nordisk. Dr. Lang is a board-certified oncologist and hematologist. He received his medical education at the Fourth Military Medical University in Xi’an and PhD in Biochemistry at Rush University in Chicago.
Paul Theron
Paul qualified as a physician, in South Africa, more than 30 years ago. Since then he has worked in private practice as a general practitioner and in various roles, from medical manager to medical director, in the pharmaceutical industry, covering Boehringer Ingelheim, AstraZeneca, Takeda and Merck. Other current roles include Executive member of MAPS JPAC and Past President of APPA. Currently he is responsible for strategy and operations in APAC and has a special interest in the future of digital health and how it will be implemented in the future
